Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly, NIAID to Study Baricitinib in COVID-19 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lilly, NIAID to Study Baricitinib in COVID-19

Baricitinib's anti-inflammatory activity has been hypothesized to have a potential benefit in COVID-19

By: Contract Pharma

Contract Pharma Staff

Eli Lilly and Co. has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), to study baricitinib as an arm in NIAID’s Adaptive COVID-19 Treatment Trial. The study will evaluate safety and efficacy of baricitinib as a potential treatment for hospitalized patients with COVID-19, beginning this month in the U.S. with a planned expansion to additional sites. Results are expected within the next two months.

Baricitinib, an oral JAK1/JAK2 inhibitor marketed as OLUMIANT, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis. Given the inflammatory cascade seen in COVID-19, baricitinib’s anti-inflammatory activity has been hypothesized to have a potential benefit in COVID-19 and warrants further study in patients with this infection.

Lilly is also advancing LY3127804, an investigational selective monoclonal antibody against Angiopoietin 2 (Ang2), to Phase II testing in pneumonia patients hospitalized with COVID-19 who are at a higher risk of progressing to acute respiratory distress syndrome (ARDS). Ang2 is known to be elevated in ARDS patients and Lilly will test whether inhibiting the effects of Ang2 with a monoclonal antibody can reduce the progression to ARDS or the need for mechanical ventilation in COVID-19 patients. This trial will begin later this month at several U.S. centers.  

Lilly currently does not anticipate shortages for any of its medicines, including baricitinib, which remains widely available in countries where it is approved. Should research efforts for baricitinib in COVID-19 prove successful, Lilly will continue to create adequate supply to support both appropriate clinical and investigational use.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics